Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

Rheumatoid arthritis (RA) is a chronic systemic autoimmune condition which affects approximately 1% of the adult population worldwide and is characterized by joint inflammation, with extra-articular features being common. Interleukin 6 (IL-6) is one of the chief pro-inflammatory cytokines found in t...

Full description

Bibliographic Details
Main Authors:	Negoescu, Andra F., Östör, Andrew J. K.
Format:	Online
Language:	English
Published:	Springer Healthcare 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883250/

Similar Items

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
by: Besada, Emilio
Published: (2014)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
by: Shetty, Anjali, et al.
Published: (2014)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
by: Mahamid, Mahmud, et al.
Published: (2011)

Review of tocilizumab in the treatment of rheumatoid arthritis
by: Okuda, Yasuaki
Published: (2008)

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
by: Nakashima, Yasuharu, et al.
Published: (2014)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
by: Rubbert-Roth, Andrea, et al.
Published: (2016)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
by: Pers, Yves-Marie, et al.
Published: (2011)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
by: Ogata, Atsushi, et al.
Published: (2012)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
by: Yilmaz, Sedat, et al.
Published: (2013)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
by: Ogata, Atsushi, et al.
Published: (2014)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
by: Kivitz, Alan, et al.
Published: (2014)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
by: Rossella Talotta, et al.
Published: (2018-06-01)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
by: Ogata, Atsushi, et al.
Published: (2015)

Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations
by: Wang, Geng, et al.
Published: (2015)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
by: Malaviya, Anshuman P, et al.
Published: (2012)

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
by: Diamantopoulos, Alex, et al.
Published: (2014)

Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient
by: Izquierdo, J. H., et al.
Published: (2012)

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
by: Burmester, Gerd R, et al.
Published: (2016)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
by: Schiff, Michael
Published: (2013)

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review
by: Al-Shakarchi, Israa, et al.
Published: (2013)

Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis
by: Sato, Tomohito, et al.
Published: (2014)

Dramatic radiographic repair by tocilizumab in a very elderly patient with rheumatoid arthritis
by: Watanabe, Ryu, et al.
Published: (2014)

Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
by: Okamura, Koichi, et al.
Published: (2014)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
by: Mahamid, Mahmud, et al.
Published: (2011)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
by: Koike, Takao, et al.
Published: (2011)

Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis
by: Mokuda, Sho, et al.
Published: (2013)

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
by: Mori, Shunsuke, et al.
Published: (2013)

Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis
by: Mori, Shunsuke, et al.
Published: (2012)

Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis
by: Szeto, Matthew Chak Hin, et al.
Published: (2016)

Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
by: Narváez, Javier, et al.
Published: (2015)

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance
by: Chiu, Yee, et al.
Published: (2012)

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
by: Burmester, Gerd R, et al.
Published: (2014)

Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)
by: Ohta, Shuji, et al.
Published: (2014)

Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
by: Kivitz, Alan, et al.
Published: (2016)

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
by: Bykerk, Vivian P, et al.
Published: (2012)

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
by: Burmester, Gerd R, et al.
Published: (2016)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
by: Rakieh, Chadi, et al.
Published: (2014)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
by: Yamaguchi, Ken-ichi, et al.
Published: (2012)

Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
by: Curtis, J. R., et al.
Published: (2016)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
by: Kiely, Patrick D. W., et al.
Published: (2012)